This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A compound of formula (I):

wherein

P¹ and P² independently represent a polyethylene glycol (PEG) moiety;

 Z^{1}_{7} , and Z^{2} and Z^{3} independently represent a polyclonal, monoclonal, multi-valent, multi-specific, humanized or chimeric antibody, a single chain antibody, a Fab fragment, a Fab' or F(ab')₂ fragment, or an epitope-binding fragment thereof;

 X^{1} , and X^{2} and X^{3} independently represent \mathbb{CR}^{4} -or N;

 A^1 and A^2 independently represent -CONH-, -NHCO-, -OC(O)N(R^2) , -N(R^2)C(O)O- or -NHCONH-;

B¹, and B² and B³ independently represent -CONH or -CO-;

 V^{1} , and V^{2} and V^{3} independently represent a covalent bond or $(CH_{2})_{v}$ -;

W1 and W2 independently represent a covalent bond or -(CH2)w-;

 Y^{1} , and Y^{2} and Y^{3} independently represent -(CH₂)_v-;

 L^{1}_{5} and L^{2} and L^{2} independently represent a maleimide moiety residue, each of which is covalently linked to Z^{1} and Z^{2} , respectively, and each of which is covalently linked through the maleimide nitrogen atom to Y^{1} and Y^{2} , respectively;

 $M^1 \ \text{and} \ M^2 \text{-independently represent a covalent bond or } \underline{\text{represents}} \ \text{-} (CH_2)_m \text{-};$

R¹-represents hydrogen or C₁₋₄ alkyl;

R² represents hydrogen or C₁₋₄ alkyl;

n is zero, 1 or 2;

v is 1, 2, 3 or 4;
w is 1, or 2, 3 or 4;
y is 1, 2, 3, 4, 5 or 6; and m is 1, 2 or 3.

- 2. (Currently amended) A compound as claimed in claim 1 wherein Z^1 , and Z^2 and Z^3 independently represent a whole antibody or a functionally active antibody fragment or derivative.
- 3. (withdrawn and currently amended) A compound of formula (H III):

```
wherein
```

```
L<sup>11</sup>, L<sup>12</sup> and L<sup>13</sup> represent groups that attach residues Z<sup>1</sup>, Z<sup>2</sup> and Z<sup>3</sup>, respectively, or
that are converted into groups that attach residues Z<sup>1</sup>, Z<sup>2</sup> and Z<sup>3</sup>, respectively;
           Z<sup>1</sup>, Z<sup>2</sup> and Z<sup>3</sup> independently represent the residue of a biologically active moiety;
           P<sup>1</sup> and P<sup>2</sup> independently represent a polymer residue polyethylene glycol (PEG)
moiety;
           X_{\frac{1}{2}}^{1} and X_{\frac{2}{2}}^{2} and X_{\frac{2}{2}}^{3}-independently represent CR^{\frac{1}{2}} or N;
           A^1 and A^2 independently represent -CONH. -NHCO-. -OC(O)N(\mathbb{R}^2).
-N(R<sup>2</sup>)C(O)O-or-NHCONH-;
           B^{1}_{\tau} and B^{2} and B^{3} independently represent -CONH-or -CO-;
           V_{\overline{a}}^{1} and V_{\overline{a}}^{2} and V_{\overline{a}}^{2} independently represent a covalent bond or (CH<sub>2</sub>), -;
           W<sup>1</sup> and W<sup>2</sup> independently represent a covalent bond or -(CH<sub>2</sub>)<sub>w</sub>-;
           Y^{1} and Y^{2} and Y^{2} independently represent -(CH<sub>2</sub>)<sub>v</sub>-:
           L<sup>1</sup>, L<sup>2</sup> and L<sup>3</sup> independently represent a maleimide moiety;
           M<sup>1</sup> and M<sup>2</sup> independently represent a covalent bond or represents -(CH<sub>2</sub>)<sub>m</sub>-;
           R<sup>1</sup> represents hydrogen or C<sub>1-4</sub>-alkyl;
           R<sup>2</sup> represents hydrogen or C<sub>1-4</sub> alkyl;
           n is zero, 1 or 2;
           v is 1, 2, 3 or 4;
           w is 1_{7} or 2_{7} or 4_{7};
           y is 1, 2, 3, 4, 5 or 6; and
           m is <del>1,</del> 2 <del>or 3</del>.
```

- 4. (cancelled))
- 5. (cancelled)

- 6. (cancelled)
- 7. (cancelled)
- 8. (currently amended) A compound as claimed in claim 1 that is

 DiFab'-conjugated N,N'-bis-[4-maleimidylbutyl]-2,3-bis-(3-(methoxy-polyethoxy)
 propionylamino) succinamide;

DiFab'-conjugated 3-maleimidyl-N-(2-{[3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino}-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide; or

DiFab'-conjugated 3-maleimidyl-N-(2-{[3-(maleimidyl)-propionyl]-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-amino}-ethyl)-N-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-propionamide.

- 9. (withdrawn and currently amended) A compound as claimed in claim 4 that is N,N'-Bis [4-maleimidylbutyl]-2,3-bis (3 (methoxy-polyethoxy) propionylamino)-succinamide;
- 3-Maleimidyl-N-(2-{[3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino}-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide; or
- 3-Maleimidyl-N-(2-{[3-(maleimidyl)-propionyl]-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-amino}-ethyl)-N-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-propionamide.
- 10. (previously presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in association with one or more pharmaceutically acceptable carriers, excipients or diluents.